BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36195163)

  • 1. Evaluating the Downstream Revenues of a Self-Pay Bi-Parametric Prostate MRI Program.
    Parikh KD; Declouette B; Chen M; Rao S; Smith DA; Bittencourt LK; Paspulati RM; Ramaiya NH; Tirumani SH
    Urology; 2023 Jan; 171():109-114. PubMed ID: 36195163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
    Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
    Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.
    Merisaari H; Jambor I; Ettala O; Boström PJ; Montoya Perez I; Verho J; Kiviniemi A; Syvänen K; Kähkönen E; Eklund L; Pahikkala T; Vainio P; Saunavaara J; Aronen HJ; Taimen P
    J Magn Reson Imaging; 2019 Nov; 50(5):1641-1650. PubMed ID: 30903647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology.
    Noh TI; Shim JS; Kang SG; Cheon J; Lee JG; Lee JH; Kang SH
    Sci Rep; 2022 Apr; 12(1):6964. PubMed ID: 35484364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Lee W; Lim B; Kyung YS; Kim CS
    Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biparametric
    Scialpi M; Prosperi E; D'Andrea A; Martorana E; Malaspina C; Palumbo B; Orlandi A; Falcone G; Milizia M; Mearini L; Aisa MC; Scialpi P; DE Dominicis C; Bianchi G; Sidoni A
    Anticancer Res; 2017 Mar; 37(3):1263-1271. PubMed ID: 28314291
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [No Abstract]   [Full Text] [Related]  

  • 12. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy.
    Sanguineti G; Bertini L; Faiella A; Ferriero MC; Marzi S; Farneti A; Landoni V
    Tumori; 2021 Feb; 107(1):55-63. PubMed ID: 32180511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
    Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
    J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of
    García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate.
    Brant A; Lewicki P; Rhodes S; Arenas-Gallo C; Strasser MO; Zhu A; Ponsky L; Shoag JE
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):252-256. PubMed ID: 36717642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.